Latest Orthopaedics News

Osteopore Limited reported a 6% increase in revenue to $1.56 million for the half-year ended June 2025, alongside a slight rise in net loss driven by expanded product development and compliance costs. The company secured key regulatory approvals and broadened its distribution footprint in Asia and the US.

Paragon Care Limited reported solid FY25 results with revenue climbing to $3.61 billion and underlying EBITDA rising 3%, driven by successful integration and expansion into new healthcare segments.

Desane Group Holdings Limited reported a strong FY25 with net profit after tax doubling to $3.3 million, supported by a $6.2 million uplift in property valuations and key lease extensions securing future rental income.

Osteopore Limited has won tender bids to supply its innovative orthopaedic implants to two major public hospitals in Vietnam, marking a significant step in its Asia Pacific expansion.

Osteopore Limited has posted a record AUD 835K revenue in Q2 CY25, driven by strong APAC sales and new European market access following EU MDR clearance. The company also advances clinical trials and refreshes key distribution channels.

Osteopore Limited has gained Swiss market approval for its 3D-printed bioresorbable implants under the EU Medical Device Regulation, completing its European product portfolio and strengthening its partnership with Zimmer Biomet.

ReNerve Limited has entered a strategic partnership with Berkeley Biologics to develop and commercialise two new tissue-based product ranges, aiming to expand its footprint in the US surgical market by the end of 2025.

Desane Group Holdings has secured a seven-year lease extension with Signature Orthopaedics at its Lane Cove property, guaranteeing $5 million in rental income through 2032. This deal reinforces Desane’s strategy to maintain stable medium-term cash flows.

Osteopore Limited reported a robust 26% quarter-on-quarter revenue increase in Q1 CY25, bolstered by a key Singapore subsidy listing and a strategic pivot away from its dental project to sharpen commercial focus.

EBOS Group Limited’s interim results for H1 2025 reveal a notable decrease in revenue and profit compared to the prior year, yet the company maintains its interim dividend, signaling confidence despite headwinds.

EBOS Group Limited posted robust interim results for H1 FY25, with underlying EBITDA rising 7.1% excluding the Chemist Warehouse Australia contract, driven by strong organic growth and strategic investments. The company maintained its dividend and reiterated FY25 EBITDA guidance between $575 million and $600 million.

Osteopore Limited reports a robust 27% year-over-year revenue increase despite operational headwinds, underpinned by new collaborations in stem cell therapies and expanded market access in Brazil and Singapore.